Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Inclusion Criteria:

Subjects with chronic, plaque-type psoriasis for at least 6 months
Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than 3, and greater than 10% body surface area
Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or systemic therapies)

Exclusion Criteria:

Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic and guttate psoriasis)
Drug induced psoriasis
Use of other psoriasis treatments during the study
Prior use of etanercept
Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the IL-17 receptor
Pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment
Significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc.
History of an ongoing, chronic or recurrent infection or evidence of tuberculosis
Allergy to rubber or latex

Other protocol-defined inclusion/exclusion criteria may apply